Loading
A phase 2 trial of Nemtabrutinib in chronic lymphocytic leukaemia, run by Merck Sharp & Dohme LLC, now recruiting.
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) is a phase 2 interventional study registered as NCT04728893 by Merck Sharp & Dohme LLC, with 490 participants planned, started 2021-04-05 and due to reach its primary completion in 2029-01-04. Interventions recorded: Nemtabrutinib. Conditions listed: Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Nemtabrutinib, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Nemtabrutinib, Chronic lymphocytic leukaemia, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Nemtabrutinib, Chronic lymphocytic leukaemia, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Nemtabrutinib, Chronic lymphocytic leukaemia, Merck & Co. (MSD), Small-molecule kinase inhibitors.
Shares Nemtabrutinib, Merck & Co. (MSD).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/